XNAS
ADPT
Market cap4.18bUSD
Oct 08, Last price
26.09USD
1D
-0.72%
1Q
23.88%
IPO
-45.98%
Name
Adaptive Biotechnologies Corp
Chart & performance
P/E
—
P/S
15.08
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.95%
Rev. gr., 5y
23.00%
Revenues
277m
+54.77%
Net income
-59m
L-62.69%
CFO
-46m
L-51.70%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Key people
Julie Rubinstein
President · since 2018
Harlan S. Robins
Co-Founder, Chief Scientific Officer · since 2009
Nancy Louise Hill
Senior Vice President - Operations · since 2018
Charles Snag
Senior Vice President - Clinical Diagnostics · since 2016
Tom Willis
Senior Vice President, General Manager - Diagnostic Products
Mark R Adams
Chief Technical Officer · since 2020
Chad M. Robins
Executive Chairman, Chief Executive Officer, Co-Founder · since 2009
Lance Baldo
Chief Medical Officer · since 2019
Sean P. Nolan
Chief Technical Officer · since 2014
Lead Independent Director · since 2013
Independent Director · since 2019
Independent Director · since 2013
Michael J. Pellini
Independent Director · since 2018
Andris A. Zoltners
Independent Director · since 2009
Legal address
300 DESCHUTES WAY SW STE 208 MC-CSC1
TUMWATER, WA 98501
US
TUMWATER, WA 98501
US
Headquarters
1165 Eastlake Ave E
Seattle, WA 98109
US
Seattle, WA 98109
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||